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Abstract: The antiresorptive drug elcatonin (ECT) is known to relieve pain in postmenopausal 
women with osteoporosis. A prospective open-labeled trial was conducted to compare the effects 
of short-term combined treatment with alendronate (ALN) and ECT on bone mineral density 
(BMD) and bone turnover with those of single treatment with ALN in postmenopausal women 
with osteoporosis. Two hundred and five postmenopausal osteoporotic women (mean age: 
70 years) were recruited in our outpatient clinic. Forty-six women with back pain were treated 
with ALN and ECT (intramuscular, 20 units a week), and 159 women without obvious back 
pain were treated with ALN alone. The lumbar BMD, urinary levels of cross-linked N-terminal 
telopeptides of type I collagen (NTX), and serum levels of alkaline phosphatase (ALP) were 
measured during the six-month treatment period. The baseline characteristics, except for age, 
body weight and number of patients with prevalent vertebral fractures, were not significantly 
different between the two groups. The mean increase rate in the lumbar BMD at six months 
was similar in the ALN (+4.41%) and ALN+ECT (+5.15%) groups, following similar reduction 
rates in urinary NTX levels (-40.2% and -43.0%, respectively, at three months) and serum 
ALP levels (-19.0% and -19.7%, respectively, at six months). These results were consistent 
even after adjustments for age, body weight, and number of patients with prevalent vertebral 
fractures. The present study in postmenopausal osteoporotic women confirmed that the effects 
of short-term combined treatment with ALN and ECT on lumbar BMD and bone turnover in 
patients with back pain appeared to be comparable to those of single treatment with ALN in 
patients without obvious back pain.
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Background
Osteoporosis most commonly affects postmenopausal women, placing them at a 
significant risk for fractures. Alendronate (ALN) and intramuscular elcatonin (ECT) 
are widely used for the treatment of postmenopausal osteoporosis in Japan. ALN 
is a bisphosphonate, which regulates bone turnover through the suppression of 
osteoclastic activity.1 Current evidence suggests the antifracture efficacy and safety 
of ALN in postmenopausal women with osteoporosis.2–4 On the other hand, ECT 
is a derivative of eel calcitonin synthesized by substituting an ethylene bond for its 
disulfide bond.5 Intramuscular ECT was developed in Japan and has been shown to 
have biological activity comparable to that of natural eel calcitonin.5–7 It has also 
been reported in vivo and in vitro studies that ECT suppresses bone resorption.7,8 
ECT has been reported to increase metacarpal and forearm bone mineral density Therapeutics and Clinical Risk Management 2009:5 500
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(BMD) in postmenopausal women with osteoporosis.9,10 
A recent study shows that ECT is useful for relieving pain 
and improving quality of life in postmenopausal women 
with osteoporosis.11 However, there is no evidence showing 
that ECT significantly reduces the incidence of fractures.12 
Therefore, ECT must primarily be used to relief pain in 
patients with osteoporosis. Its use is limited to a maximum 
period of six months in Japan.
Because of the above-mentioned differential effects, 
combined treatment with ALN and ECT might be useful for 
preventing fractures and relieving pain in postmenopausal 
osteoporotic women with back pain. However, combined 
treatment with two anti-resorptive drugs could induce a 
severe suppression of bone turnover. The effects of combined 
treatment with these two drugs on BMD and bone turnover 
remain to be established in postmenopausal osteoporotic 
women with back pain. The objective of this prospective 
open-labeled trial was to compare the effects of short-term 
(six months) combined treatment with ALN and ECT on 
BMD and bone turnover in postmenopausal osteoporotic 
women with back pain with the effects of single treatment 
with ALN only in those without obvious back pain. The 




Two hundred and thirty-four postmenopausal women 
(age range: 48–89 years; mean age: 70.1 years) were recruited 
in the outpatient clinic of Keiyu Orthopaedic Hospital 
(Gunma, Japan) during the three-year period between 
October 2005 and September 2008. Inclusion criteria were 
postmenopausal women with osteoporosis with or with-
out a history of osteoporotic fractures. Exclusion criteria 
were histories of reflux esophagitis, gastric or duodenal 
ulcer, gastrectomy, or bone diseases including primary 
hyperparathyroidism, hyperthyroidism, Cushing syndrome, 
multiple myeloma, rheumatoid arthritis, and osteogenesis 
imperfecta. Subjects who had ever taken medication known 
to affect bone metabolism were also excluded. None of the 
subjects included in the present trial participated in regular 
sporting activities or were heavy laborers.
All the patients had been diagnosed as having osteoporosis 
according to the Japanese diagnostic criteria.13,14 Namely, 
patients with a BMD  70% of the young adult mean 
(YAM) or of 70%–80% of the YAM along with a history 
of osteoporotic fractures were diagnosed as having 
osteoporosis. A preliminary screening included a medical 
history, physical examination, plain X-rays of the thoracic 
and lumbar spine, lumbar BMD measurement, and blood 
and urinary biochemical tests including serum calcium, 
phosphorus, and total alkaline phosphatase (ALP) and 
urinary cross-linked N-terminal telopeptides of type I 
collagen (NTX).
Fifty-four women with back pain were treated with 
ALN (5 mg/day or 35 mg/week) and ECT (intramuscular, 
20 units a week) (the ALN+ECT group), and 180 women 
without obvious back pain were treated with ALN alone 
(5 mg/day or 35 mg/week) (the ALN group). The doses 
indicated in the parentheses above are the doses used in 
Japan for the treatment of postmenopausal women with 
osteoporosis and have been recognized as being safe and 
effective.15–17 Daily ALN and intramuscular ECT treatment 
were available throughout the study period, but weekly ALN 
treatment only became available after October 2006. All the 
subjects in both groups were given a pamphlet instructing 
them to consume about 800 mg of dietary calcium and 
400 IU of dietary vitamin D daily during the study period. 
All of the subjects in the ALN+ECT group were also 
treated with oral non-steroidal anti-inflammatory drugs 
(NSAIDs) (zaltoprofen), percutaneous NSAIDs (ointment 
or compress), and/or trigger point injections of lidocaine 
hydrochloride due to back pain. The duration of the trial 
was six months.
The urinary levels of NTX were measured at three months 
after the start of treatment. The serum levels of calcium, 
phosphorus, and ALP and the lumbar BMD were measured 
at six months after the start of treatment. The incidence of 
clinical fractures, which were diagnosed with radiographs 
or magnetic resonance images, was assessed during the 
six-month treatment period. Informed consent was obtained 
from each participant prior to her participation in the study. 
This protocol was approved by the Ethics Committee of 
Keiyu Orthopaedic Hospital.
Assessment of vertebral fractures
Plain lateral X-ray films of the thoracic and lumbar spine 
were obtained to detect evidence of morphometric vertebral 
fractures. According to the Japanese criteria, a vertebral 
fracture was defined according to the vertebral height on lateral 
X-ray films.13,14 Briefly, the vertebral height was measured 
at the anterior (A), central (C), and posterior (P) parts of the 
vertebral body, and the presence of a vertebral fracture was 
confirmed when (1) a reduction in the vertebral height of 
more than 20% (A, C, and P) compared with the height of the 
adjacent vertebrae was observed, (2) the C/A or C/P was less Therapeutics and Clinical Risk Management 2009:5 501
Alendronate and elcatonin in osteoporosis treatment Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
than 0.8, or (3) the A/P was less than 0.75. The assessment for 
vertebral fractures was performed at the T4–L4 level.
Measurement of lumbar BMD
The BMD of the lumbar spine (L1–L4) in the anteroposterior 
view was measured using dual-energy X-ray absorptiometry 
(DXA) with a Hologic QDR 1500W apparatus (Bedford, MA, 
USA). The coefficient of variation (100 × standard deviation/
mean) of five measurements with repositioning within 
72 hours each time was less than 1.2% in three persons.
Measurement of biochemical markers
Urine and blood samples were obtained from the subjects 
in the morning between 9:00 am and 11:00 am. The urinary 
levels of NTX were measured using an enzyme-linked 
immunosorbent assay. The serum levels of calcium, phos-
phorus, and ALP were measured using standard laboratory 
techniques.
statistical analysis
Data were expressed as the mean ± standard deviation (SD). 
Cross-sectional data comparisons between the two groups 
were performed using an unpaired t-test and analysis of 
covariance (ANCOVA). The significance of longitudinal 
changes in the parameters in a group was determined using 
a one-way analysis of variance (ANOVA) with repeated 
measurements. Longitudinal changes in the parameters were 
compared between the two groups using a two-way ANOVA 
with repeated measurements. The ratio of daily to weekly 
ALN, percentage of women with fractures, and incidence of 
clinical fractures were compared between the two groups by 
the Fisher’s exact test. All statistical analyses were performed 
using the StatView-J5.0 program (Windows version; SAS 
Institute, Cary, NC, USA). A significance level of p  0.05 
was used for all the comparisons.
Results
Dropout of study subjects
Twenty (11.7%) women in the ALN group and 8 (14.8%) 
women in the ALN+ECT group discontinued treatment during 
the six-month period. The main reasons for the dropout from 
the trial were difficulty in compliance, epigastric pain, gastric 
ulcers, heartburn, and tooth treatment (extraction) concern-
ing osteonecrosis of the jaw in the ALN group, and difficulty 
in compliance, epigastric pain and loss to follow-up in the 
ALN+ECT group (Table 1). Facial flushing was observed in 
relation to ECT treatment in three women, but this symptom 
was mild and required no treatment or withdrawal of the 
drug treatment. No serious adverse events necessitating 
hospitalization were observed in either group. The trial was 
completed in 159 (88.3%) women in the ALN group and 
46 (85.2%) women in the ALN+ECT group (age range: 49–89 
years; mean age: 70.0 years), and the data for these women 
were used in the subsequent statistical analyses.
Characteristics of the study subjects
Table 2 shows the baseline characteristics of the study 
subjects who completed the six-month trial. The patients 
in the ALN+ECT group were older and their body weights 
were lower than those in the ALN group. The number of 
vertebral fractures was greater in the ALN+ECT group than 
in the ALN group. However, no significant differences in 
the other baseline characteristics were observed between the 
two groups. The mean levels of urinary NTX in both groups 
suggested high turnover osteoporosis (the normal range for 
Japanese women: 9.3–54.3 nmol BCE/mmol Cr).18
Changes in lumbar BMD  
and biochemical markers
Table 3 shows the changes in the lumbar BMD and 
biochemical markers. Urinary NTX levels were reduced 
to the normal range for Japanese women (9.3–54.3 nmol 
BCE/mmol Cr)18 in both groups. The serum ALP levels 
stayed within the normal range (135–310 IU/L) during the 
six-month period of treatment in both groups. The mean 
increase rate in the lumbar BMD at six months was 4.41% 
in the ALN group and 5.15% in the ALN+ECT groups. The 
respective mean decrease rates in the urinary NTX level 
at three months were 40.2% and 43.0%, and those of the 
serum ALP levels at six months were 19.0% and 19.7%. No 
significant differences in the change in the lumbar BMD, 
serum levels of calcium, phosphorus or ALP, and urinary 
levels of NTX were observed between the two groups when 
analyzed using an unpaired t-test. The statistical results of 
Table 1 Reasons for dropout from the trial
ALN group (n = 20) ALN+ECT group (n = 8)
Difficulty in compliance (n = 15) Difficulty in compliance (n = 6)
Epigastric pain (n = 2) Epigastric pain (n = 1)
Gastric ulcer (n = 1) Loss to follow-up (n = 1)
Heartburn (n = 1)
Treatment (extraction) of tooth (n = 1)
Notes: Twenty (11.7%) women in the alendronate (ALN) group and eight (14.8%) 
women in the ALn + EC (ECT) group dropped out from the trial because of the 
above reasons. Namely, 88.3% (159/180) and 85.2% (46/54) of women in the respective 
groups completed the trial.Therapeutics and Clinical Risk Management 2009:5 502
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Table 2 Characteristics of study subjects
ALN group (n = 159) ALN+ECT group (n = 46) P values
ALn treatment, Daily:   Weekly 92:67 30: 16 ns
Age (years) 68.5 ± 9.7 75.3 ± 8.7 0.0001
Height (m) 1.49 ± 0.07 1.48 ± 0.06 ns
Body weight (kg) 48.9 ± 7.2 45.7 ± 6.3 0.01
Lumbar BMD (g/cm2) 0.660 ± 0.076 0.644 ± 0.080 ns
%YAM of lumbar BMD (%) 65.0 ± 7.5 63.4 ± 7.9 ns
Serum calcium (mg/dl) 9.4 ± 0.4 9.3 ± 0.4 ns
Serum phosphorus (mg/dl) 3.4 ± 0.5 3.4 ± 0.5 ns
Serum ALP (IU/l) 256 ± 65 276 ± 63 ns
Urinary NTX (nmol BCE/mmol Cr) 69.8 ± 22.2 72.2 ± 22.4 ns
Number (%) of women with prevalent vertebral fractures 55 (34.6) 29 (63.0) 0.001
Number (%) of women with history of nonvertebral fractures 10 (6.3) 1(2.2) ns
Notes: Data are expressed as the mean ± sD. Data comparison between the two groups was performed using an unpaired t-test. The ratio of daily to weekly ALn and 
percentage of women with fractures were compared by the Fisher exact test. 
Abbreviations:  ALn, alendronate; eCT, elcatonin; BMD, bone mineral density;   YAM, young adult mean;   ALP, alkaline phosphatase; nTX, cross-linked n-terminal telopeptides 
of type I collagen; BCE, bone collagen equivalent; Cr, creatinine; NS, not significant.
the ANCOVA regarding the percent changes in the lumbar 
BMD and biochemical parameters were similar even after 
adjustments for age, body weight and the number of patients 
with prevalent vertebral fractures.
Incidence of clinical fractures
Six clinical fractures were observed during the six-month 
treatment period. Vertebral fractures occurred in four women 
and a wrist fracture occurred in one woman in the ALN 
group and vertebral fractures occurred in one woman in the 
ALN+ECT group. The incidence of clinical fractures was 
3.14% in the ALN group and 2.17% in the ALN+ECT group, 
with no significant difference between the two groups.
Discussion
The objective of this trial was to compare the effects of 
short-term (six months) combined treatment with ALN 
and ECT on BMD and bone turnover with those of single 
treatment with ALN in postmenopausal women with 
osteoporosis. The present study confirmed that the effects of 
short-term (six months) combined treatment with ALN and 
ECT on lumbar BMD and bone turnover in patients with back 
pain appeared to be comparable to those of single treatment 
with ALN in patients without obvious back pain.
In postmenopausal Japanese women with osteoporosis, 
studies of ALN showed that ALN (5 mg/day) decreases 
urinary deoxypyridinoline and serum ALP levels, increases 
lumbar BMD, and prevents vertebral fractures.15,16 Our 
previous studies also showed that ALN (5 mg/day) 
decreases urinary NTX and serum ALP and increases lumbar 
BMD.19–23 The effects of ALN on bone turnover markers 
and lumbar BMD and the incidence of adverse effects 
of ALN were reported to be similar for two dosing regimens 
(5 mg/day and 35 mg/week).24 These studies imply that ALN 
(5 mg/day or 35 mg/week) decreases urinary NTX levels by 
about 36%–45% at three months and serum ALP levels by 
about 9%–30% at six months, leading to an increase in lumbar 
BMD by about 3.9%–5.4% at six months. In the present 
study, treatment with ALN (5 mg/day and 35 mg/week) alone 
increased lumbar BMD by 4.41% at six months, following 
reductions in urinary levels of NTX (-40.2% at three months) 
and serum levels of ALP (-19.0% at six months), which were 
consistent with the previous reports.15,19–23
Weekly intramuscular injections of ECT at a dose of 
20 units reportedly increased lumbar BMD by 1.87% from 
baseline over six months in postmenopausal Japanese 
women with osteoporosis.17 The mechanism for this positive 
effect of ECT on lumbar BMD remains unexplained, since 
bone turnover markers such as urinary hydroxyproline and 
serum osteocalcin did not change significantly compared 
with a control group.17 In the present study, because an 
ECT treatment-alone group was not approved by the ethical 
committee, the effects of administration of ECT alone on 
bone turnover markers and lumbar BMD remains uncertain. 
However, because ECT reportedly does not have a significant 
antifracture effect against vertebral fractures in postmeno-
pausal women with osteoporosis,12 combined treatment with 
ECT and a potent antifracture drug, rather than single treat-
ment with ECT alone, might be desirable for the prevention 
of fractures and the relief of pain.Therapeutics and Clinical Risk Management 2009:5 503
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Bone strength reflects both bone mass and bone quality, 
and bone quality is derived from the bone architecture, 
turnover, damage accumulation, mineralization, and 
bone matrix.25 In particular, a reduction in bone turnover 
markers has been reported to be important for reducing 
the incidence of fractures in postmenopausal women with 
osteoporosis.26,27 In the present study, both treatment with 
ALN alone and treatment with ALN and ECT reduced 
urinary NTX levels to the normal range for Japanese women 
(9.3–54.3 nmol BCE/mmol Cr).18 The serum ALP levels 
stayed within the normal range (135–310 IU/L) during 
the six-month period of treatment in both groups, even 
though the level decreased significantly after treatment. 
The similar increase in lumbar BMD at six months might 
suggest a similar reduction in bone turnover. Marked 
reductions in bone turnover markers to below the normal 
ranges might not necessarily be a concern in the ALN+ECT 
group when the duration of combined treatment with the 
two drugs is limited to a maximum of six months. The 
antiresorptive effect of ECT and the subsequent increase 
in BMD might have been rather modest, and additional 
changes in the bone turnover markers and lumbar BMD 
might have been masked by the potent effects of ALN in 
the ALN+ECT group.
Calcitonin reduces pain via its action on the central 
nervous system.28 The serotonergic system in the spinal 
cord (dorsal horn) might be involved in antinociception. 
There are no significant differences in the analgesic 
effect of eel and salmon calcitonins and their influence on 
the morphine-analgesia.29 Estrogen deficiency not only causes 
bone loss, but also affects the spinal serotonergic system 
(serotonergic receptor expression), resulting in hyperalgesia. 
Calcitonin restores this change in the serotonergic system 
and has an analgesic action in postmenopausal women. Thus, 
ECT has been used for the treatment of postmenopausal 
osteoporotic women with back pain. In the present study, the 
pain relief effect of ECT itself was not assessed, since all of 
the subjects in the ALN+ECT group were also treated with 
oral NSAIDs, percutaneous NSAIDs (ointment of compress), 
and/or trigger point injections of lidocaine hydrochloride.
Twenty women (11.8%) in the ALN group and eight 
(14.8%) women in the ALN+ECT group dropped out of the 
present trial. The main reasons for dropout were difficulty 
in compliance and epigastric problems related to ALN. 
Facial flushing was observed in relation to ECT treatment 
in three women, but this symptom was mild and required no 
additional treatment or withdrawal of the drug. No serious 
adverse events necessitating hospitalization were observed. 
Table 3 Changes in lumbar BMD and biochemical markers
Baseline At follow-up Percent change One- and two-way ANOVA
Lumbar BMD(g/cm2)  
  ALN group (n = 159)  
  ALn+ECT group (n = 46)  
  group difference
0.660 ± 0.076  
0.644 ± 0.080  
ns
0.688 ± 0.079  
0.676 ± 0.084  
ns
+4.41 ± 4.92  
+5.15 ± 7.74  
ns
P  0.0001  
P  0.0001  
ns
Serum calcium (mg/dl)  
  ALN group (n = 159)  
  ALn+ECT group (n = 46)  
  group difference
9.4 ± 0.4  
9.3 ± 0.4  
ns
9.3 ± 0.5  
9.2 ± 0.4  
ns
-0.94 ± 4.56  
-0.96 ± 4.64  
ns
P  0.01  
ns  
ns
Serum phosphorus (mg/dl)  
  ALN group (n = 159)  
  ALn+ECT group (n = 46)  
  group difference
3.4 ± 0.5  
3.4 ± 0.5  
ns
3.3 ± 0.5  
3.4 ± 0.4  
ns
-2.59 ± 16.8  
+0.36 ± 11.7  
ns
P  0.01  
ns  
ns
Serum ALP (IU/l)  
  ALN group (n = 159)  
  ALn+ECT group (n = 46)  
  group difference
256 ± 65  
276 ± 63  
ns
201 ± 53  
221 ± 58  
ns
-19.0 ± 21.1  
-19.7 ± 20.0  
ns
P  0.0001  
P  0.0001  
ns
Urinary NTX (nmol BCE/mmol Cr)  
  ALN group (n = 1 59)  
  ALn+ECT group (n = 46)  
  group difference
68.9 ± 22.2  
72.2 ± 22.4  
ns
39.4 ± 21.6  
38.7 ± 16.4  
ns
-40.2 ± 30.0  
-43.0 ± 36.9  
ns
P  0.0001  
P  0.0001  
ns
Notes: Data are expressed as the mean ± sD. The lumbar BMD and serum levels of biochemical markers were measured at baseline and 6 months after the start of the treat-
ment. The urinary levels of nTX were measured at baseline and 3 months after the start of the treatment. Cross-sectional comparison of the data between the two groups was 
performed using an unpaired t-test. The significance of longitudinal changes in the parameters within a group was determined using a one-way analysis of variance (ANOVA) 
with repeated measurements. Longitudinal changes in the parameters were compared between the two groups using a two-way ANOVA with repeated measurements. 
Abbreviations: ALn, alendronate; eCT, elcatonin; BMD, bone mineral density;   ALP, alkaline phosphatase; nTX, cross-linked n-terminal telopeptides of type I collagen; 
BCE, bone collagen equivalent; Cr, creatinine; ANOVA, analysis of variance; NS, not significant.Therapeutics and Clinical Risk Management 2009:5 504
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Thus, treatment with ALN alone and treatment with ALN+ECT 
were both safe and well tolerated in postmenopausal Japanese 
women with osteoporosis.
The present study has several notable limitations. First, 
the study was not a double-blind trial but an open-labeled 
one, and ECT was used to relieve pain only in women with 
back pain. Therefore, some of the results might be biased. 
If age, body weight, and number of patients with prevalent 
vertebral fractures had been matched between the groups, 
the results of this study might have been different. Second, 
the number of study subjects was relatively small and 
not sufficiently large to lend sufficient power to allow a 
conclusion regarding the effects of these drugs on fractures. 
Third, it has been reported that NSAIDs such as ibuprofene 
and acetaminophen affect bone resorption markers including 
urinary NTX.30 The simultaneous use of these drugs may 
modify the effect of ALN and/or ECT on bone markers. 
Although the effect of zaltoprofen on bone metabolism 
has not yet been established, its influence on bone markers 
must have been taken into account in the ALN+ECT group. 
Fourth, we just recommended for all the participants to 
consume about 800 mg of dietary calcium and 400 IU of 
dietary vitamin D daily using a pamphlet. So, we were not 
able to evaluate how much calcium and vitamin D were 
exactly consumed by the participants. Thus, a double-blind 
randomized placebo-controlled study with a sufficient 
number of subjects is needed to confirm the results of the 
present study.
In conclusion, the present prospective open-labeled trial 
in postmenopausal osteoporotic women confirmed that the 
effects of short-term combined treatment with ALN and ECT 
on lumbar BMD and bone turnover in patients with back pain 
appeared to be comparable with those of single treatment 
with ALN in patients without obvious back pain. Marked 
reductions in bone turnover markers to below the normal 
ranges might not necessarily be a concern in the treatment 
of ALN plus ECT when the duration of combined treatment 
with the two drugs is limited to a maximum of six months.
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